Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Institution
- Keyword
-
- Ankylosing Spondylitis (1)
- Diffuse (1)
- Disease Progression (1)
- Etanercept (1)
- Fibrillar Collagens (1)
-
- Fibrosis (1)
- Gene Expression (1)
- Ginger (1)
- Humans (1)
- Immunosuppressive Agents (1)
- Lung (1)
- Middle Aged (1)
- Mycophenolic Acid (1)
- Osteoarthritis (1)
- Prognosis (1)
- Prospective Studies (1)
- Respiratory Function Tests (1)
- Scleroderma (1)
- Scleroderma, Diffuse (1)
- Skin (1)
- Time Factors (1)
- Treatment Outcome (1)
- [RSTDPub] (1)
- Publication
- Publication Type
Articles 1 - 3 of 3
Full-Text Articles in Rheumatology
A Prospective Observational Study Of Mycophenolate Mofetil Treatment In Progressive Diffuse Cutaneous Systemic Sclerosis Of Recent Onset., Fabian A. Mendoza, Md, Sarah J. Nagle, Jason B. Lee, Md, Sergio A. Jimenez
A Prospective Observational Study Of Mycophenolate Mofetil Treatment In Progressive Diffuse Cutaneous Systemic Sclerosis Of Recent Onset., Fabian A. Mendoza, Md, Sarah J. Nagle, Jason B. Lee, Md, Sergio A. Jimenez
Jefferson Institute of Molecular Medicine Papers and Presentations
OBJECTIVE: A prospective observational study of mycophenolate mofetil (MMF) treatment in patients with diffuse progressive cutaneous systemic sclerosis (SSc) of recent onset.
METHODS: Twenty-five previously untreated consecutive patients with recent-onset (< 24 mo) diffuse progressive cutaneous SSc received MMF as the only disease-modifying therapy. Modified Rodnan skin score (mRSS) and affected body surface area (BSA) were compared from initiation of MMF to study end. Pulmonary function tests performed at the same institution before therapy and at study end were available in 15 patients. Histopathology and real-time PCR assessment of fibrosis-related gene expression were performed before and after treatment in skin biopsies from 3 patients.
RESULTS: At 18.2 ± 8.73 months of MMF therapy (median 2000 mg/day) the mRSS decreased from 24.56 ± 8.62 to 14.52 ± 10.9 (p = 0.0004) and the affected BSA from 36% ± 16% to 14% ± 13.3% (p = 0.00001). Pulmonary function tests remained stable from initiation of MMF to the end of the study. Skin histopathology showed a remarkable reduction in accumulation of fibrotic tissue. Real-time PCR …
Is Etanercept A Safe And Effective Treatment For Ankylosing Spondylitis?, Robyn M. Albert
Is Etanercept A Safe And Effective Treatment For Ankylosing Spondylitis?, Robyn M. Albert
PCOM Physician Assistant Studies Student Scholarship
Objective: The objective of this selective EBM review is to determine whether or not etanercept is a safe and effective treatment for ankylosing spondylitis (AS).
Study Design: Review of three English language randomized control trials published in 2007, 2008, and 2010.
Data Sources: Two double-blind placebo-controlled randomized controlled trials and one placebo-controlled randomized control trial comparing etanercept to placebo were found using PubMed.
Outcomes Measured: Work instability was measured through the Ankylosing Spondylitis Work Instability Scale (AS-WIS) based on scores of 1-20. Quality of life was measured through the EuroQOL-5D (EQ-5D), which assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. …
Ginger And Osteoarthritis, Tessa Therkleson
Ginger And Osteoarthritis, Tessa Therkleson
Research outputs 2012
Ginger has been used for 1000s of years as a food and medicine; it is likely one of the most ancient remedies valued by humans. Ancient Indian and Chinese cultures reportedly used ginger for a wide variety of conditions and modern day research has found it effective as an anti-emetic and anti-inflammatory agent, when taken internally. Random controlled trials using ginger extract have been found effective in relieving symptoms of osteoarthritis. Osteoarthritis is the primary cause of musculoskeletal pain and disability in Western cultures. Current management is primarily through the use of anti-inflammatory and analgesic medication, with cortisone injections and …